Clinical advances in biological therapy for generalized pustular psoriasis: a review.

Abstract excerpt

INTRODUCTION: In 2022, U.S. Food and Drug Administration (FDA) approved the first biologics, intravenous spesolimab, for acute flare of generalized pustular psoriasis (GPP). The drug works by blocking IL-36 signaling, the key pathway of GPP. Among the known mutations causing GPP, IL36RN mutations are most common, and the presence of IL36RN mutations had been found to affect the clinical manifestations and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Disease
• Share to Biological Products
• Share to Child